Insights from Mr. Deepak Sharma, Co-Founder and CEO, MedLern, on rethinking healthcare training
Category: Health
-
Compliance Alone Will Not Build a Capable Hospital Workforce
The way hospitals train their staff has long been shaped by regulatory requirements. Training calendars are often designed around inspections, audits, and accreditation cycles. While compliance is necessary, relying on it as the primary driver of workforce training is increasingly proving insufficient. Rapid technological change, persistent staffing shortages, and rising patient expectations demand a more thoughtful and sustained approach to learning.
Market consolidation and operational pressure
Upskilling and continuous learning
Engagement and retention
Responding to regulatory and technological change
Encouraging interdisciplinary collaboration
Building competence as a culture
Impact on efficiency and patient outcomes
Looking ahead
-
As birth asphyxia persists, Johnson’s Baby scales neonatal resuscitation with training across India
With over 2 lakh nurses, midwives and paediatricians trained through a leading paediatrician association, Johnson’s Baby’s initiative focuses on the first minute of life and the importance of neonatal resuscitation
In a country where 1.25 lakh newborns die within 24 hours of birth every year, largely due to preventable complications like birth asphyxia, timely intervention has never been more critical. Responding to this challenge, Johnson’s® Baby has quietly supported a transformative public health initiative over the last 16 years: the training of more than 2 lakh healthcare professionals in Neonatal Resuscitation Protocols (NRP).
Partnering with a leading paediatrician association, the brand has helped strengthen neonatal emergency response across India. Nurses, midwives and paediatricians trained through this initiative are now equipped with life-saving skills to manage asphyxiated newborns in the first moments of life. The program aims to reinforce one powerful message that every breath matters.Neonatal resuscitation is a globally recognised, evidence-based practice that provides healthcare professionals with standardised training in assessing, supporting and reviving newborns facing difficulty breathing at birth. Despite its proven efficacy, the lack of formalised training at scale had previously limited access to such interventions in India, especially in remote and underserved regions.
“The survival of a newborn depends on correct interventions provided at the first minute of a baby’s birth. Unfortunately, these critical interventions are often compromised due to insufficient knowledge, training, and resources available to healthcare professionals,” said Manoj Gadgil, Business Unit Head – Essential Health & Skin Health and VP Marketing, Kenvue, India.He continued, “At Johnson’s® Baby, we promise to protect babies not only from their first day but from the first moment. From providing high-quality products to partnering with social impact organisations, we are passionate about helping improve the lives of babies.”
The scale of this training initiative makes it one of the largest neonatal-focused skill-building efforts in the country. Over 2 lakh healthcare workers have participated in hands-on, expert-led sessions on neonatal emergency care, intervention techniques, and structured response systems under the NRP framework.One of the standout aspects of the 2025 campaign is its culturally sensitive public engagement strategy. The latest awareness push includes a digital short film titled Pahila Saans, conceptualised by creative agency DDB Mudra. Set in a small-town hospital, the film illustrates the dramatic moment when a newborn, unable to breathe, is revived by a healthcare worker following resuscitation protocols. The emotional core of the film is the traditional Indian cradle song Sohar, reinterpreted to celebrate the power of timely medical action.
All streaming revenues generated by this musical tribute will be donated to scale the neonatal resuscitation initiative further, extending training to new regions and healthcare institutions.Malini Awasthi, the renowned folk singer who lent her voice to the project, remarked, “As a folk singer, I have always believed that music has the power to connect hearts and inspire action. The first cry of a baby is a song of hope, and through this initiative we celebrate the birth of life. It is my humble effort to ensure that no parent has to endure the heartbreak of losing a child due to a lack of timely intervention.”
The campaign’s core theme Project Golden Minute highlights the first 60 seconds after a baby’s birth as the window during which immediate care can determine life or death. In India, where healthcare disparities persist across states and regions, strengthening medical response in that one minute could significantly reduce neonatal mortality rates.Siddhesh Khatavkar and Harshada Menon, Executive Creative Directors at DDB Mudra, described the creative process as an exercise in honouring both maternal courage and the healthcare workforce. “Through this project, that precious first minute is being safeguarded by thousands of trained doctors, midwives, and healthcare workers. Saving a newborn isn’t just a medical intervention; it is an act of love,” they noted.
Johnson’s® Baby also plans to scale public outreach through multi-platform engagement including social media influencer collaborations, cinema advertisements with PVR Cinemas, and on-ground activations in maternity hospitals and community health centres. The campaign will tap into both emotional storytelling and health literacy to amplify awareness about the preventability of birth asphyxia.Over the last decade and a half, the brand has supported a paediatrician-led training framework that includes curriculum development, clinical mentoring, assessment, and ongoing feedback. These efforts have created a growing network of trained professionals who now serve as regional champions for neonatal safety.
This long-term approach distinguishes the program from short-term CSR interventions. By embedding the training within a credible institutional partnership and funding its continuity, Johnson’s® Baby has contributed to systemic change in newborn care.The program also aligns with broader national goals under initiatives such as the India Newborn Action Plan (INAP), which seeks to reduce preventable newborn deaths and stillbirths through high-impact interventions at scale. By focusing on the first minute of life—a critical, often overlooked interval the initiative addresses a gap in implementation within the healthcare delivery system
Importantly, the impact of such a program also goes beyond neonatal units. It influences policy conversations around birth preparedness, maternal training, emergency response standardisation and equitable access to skilled care. These ripple effects can help create a more resilient, inclusive public health ecosystem.As Johnson’s® Baby continues to honour its promise of supporting babies from their very first breath, the success of its 16-year partnership with India’s paediatric leadership offers a compelling example of what private-public collaboration can achieve.
In the words of a midwife in rural Maharashtra who participated in the program: “When I heard the baby cry after using what I learned in training, I felt like I had been given a superpower. That cry will stay with me forever.”
For Johnson’s® Baby, that sound is not just a milestone, it is a mission fulfilled.At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTub
-
Japan’s Teijin and India’s BioVaram enter strategic alliance to advance regenerative medicine and medical device access
The agreement covers joint work on commercializing Teijin’s SYNFOLIUMⓇ heart repair patch in India and introducing BioVaram’s exosome-based therapeutics and collagen biomaterials in Japan
In a significant move to bridge medical innovation across Asia, Teijin Limited, a technology-led global group based in Japan, has entered into a strategic partnership with BioVaram, the biotechnology arm of Hyderabad-based UR Advanced Therapeutics Pvt Ltd (URAT). The two companies have signed a formal business alliance agreement to advance the availability and development of regenerative medicine products and implantable medical devices in India and Japan.
The agreement is a dual-track collaboration that allows Teijin to evaluate and introduce BioVaram’s novel regenerative medicine innovations into Japan, while enabling BioVaram to bring select products from Teijin’s healthcare portfolio into the Indian clinical and regulatory ecosystem.One of the key components of this alliance is the proposed regulatory approval and commercialization of SYNFOLIUMⓇ, a bioabsorbable cardiovascular patch developed by Teijin Medical Technologies Co., Ltd., a group company of Teijin Limited. Designed for tissue repair in cardiovascular surgeries, this device is now being evaluated for market entry in India. The partnership aims to expedite this process through local clinical validation and regulatory compliance.
Equally important to the alliance is the potential expansion of Japan Tissue Engineering Co., Ltd. (J-TEC) products into India. J-TEC, a subsidiary of the Teijin Group, is one of Japan’s leading names in regenerative medicine. Their offerings in skin, cartilage, and tissue-engineered cellular products are currently available only in the Japanese market but are now being explored for introduction to India through this collaboration.From the Indian side, BioVaram will evaluate the development and potential approval pathways for some of its flagship innovations in Japan. This includes exosome-based diagnostics and therapeutics, extracellular matrix mimics, and bio-derived materials such as Type I atelocollagen, which are key ingredients in tissue engineering. These products will be positioned for potential development in collaboration with Japanese manufacturing and distribution channels, and technical integration will be a core area of joint planning.
Commenting on the partnership, Dr. Takayuki Nakano, Mission Executive and General Manager of the Regenerative Medicine & Implantable Medical Device Division at Teijin Limited, said the agreement represents a significant step in the group’s international expansion. “By combining the exceptional technological capabilities and expertise of both companies across the distinct healthcare markets of Japan and India, we are confident in our ability to deliver meaningful therapies that address long-standing gaps in care. This partnership builds on Teijin’s commitment to globalizing its regenerative medicine business.”Echoing the sentiment, Jaganmohan Reddy, Founder and CEO of UR Advanced Therapeutics, described the partnership as a milestone in BioVaram’s global journey. “This agreement reinforces our vision to transform India into a centre of excellence for regenerative medicine. Through collaboration with Teijin, we expand our R&D capabilities, scale our manufacturing, and gain access to a healthcare market that is both deeply advanced and open to innovation.”
Founded in 2018 and headquartered in Hyderabad, BioVaram has rapidly earned recognition as one of India’s most promising biotechnology companies in the space of regenerative medicine and cellular therapeutics. It was named a “Top 5 Startup” at BioAsia 2024 and is known for its in-house development of AI-designed peptides, therapeutic exosomes, and a proprietary portfolio of collagen-based scaffolds and ECM substitutes.On the Japanese side, Teijin brings a long-standing legacy in medical and material sciences. Established in 1918 and listed on the Tokyo Stock Exchange (TSE: 3401), Teijin Limited operates across high-performance materials and healthcare, with over 170 group companies globally. Its healthcare division includes Teijin Medical Technologies, Teijin Regenet, and J-TEC, all working across regenerative therapies, CDMO services, and implantable devices.
In 2022, Teijin consolidated these businesses into a dedicated division focused on regenerative medicine, setting a fiscal 2030 target of JPY 20 billion in global revenue from this vertical. The alliance with BioVaram is expected to play a crucial role in fulfilling this vision by adding scalable, export-ready technologies from India into Teijin’s innovation and commercialization pipeline.As part of the roadmap, the companies will jointly assess the regulatory pathways, product compatibility, technical integration, and manufacturing feasibility for several co-developed initiatives. These include cell and gene therapy, bioengineered skin and tissue products, and advanced biomaterials for surgical applications.
The collaboration also reflects a broader shift toward cross-border innovation in the healthcare sector. With Japan’s super-ageing population and India’s fast-growing biotech capabilities, the alliance between Teijin and BioVaram brings together two ecosystems that are distinct yet complementary.As regulatory consultations begin and feasibility studies move forward, both companies will continue to co-develop products that meet shared standards of efficacy, patient safety, and ethical manufacturing.
This partnership signals not only a new era of product development and global expansion but also a mutual commitment to innovation that is sustainable, accessible, and deeply rooted in science.At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTub
-
Founded by Dr Vritika Agrawal, DermaCute Opens Mumbai Flagship at New Link Road
With global dermatology market at USD 1.50 billion and India’s aesthetic segment set to reach USD 383.79 million by 2032, DermaCute opens in Mumbai offering advanced, personalised treatments in dermatology and aesthetics.
DermaCute, a dermatology and aesthetic clinic founded by Dr Vritika Agrawal, has launched its flagship centre in Mumbai, located on New Link Road, Andheri West. The clinic aims to provide advanced, evidence-based skincare and aesthetic solutions tailored to individual needs, marking its entry at a time of significant growth in the dermatology sector both globally and in India.
Globally, the dermatology market is valued at USD 1.50 billion in 2025 and projected to reach USD 2.75 billion by 2034, growing at a CAGR of 6.94%. In India, the aesthetic dermatology segment is expanding rapidly from USD 169.48 million in 2024 to an expected USD 383.79 million by 2032 driven by rising consumer demand for medically supervised, technology-driven skincare.DermaCute offers a comprehensive suite of treatments, including personalised solutions for acne, scars, pigmentation, anti-ageing, hair removal, and skin rejuvenation. The clinic combines laser technologies, non-invasive contouring, and facial enhancement techniques with a strong clinical foundation, aiming to deliver safe and lasting outcomes.
Founder and CEO Dr Vritika Agrawal, an MBBS and MD in Dermatology, brings together clinical expertise and a vision for a modern, patient-first approach. At DermaCute, our goal is to make advanced dermatological care more accessible, transparent, and effective,” she said. “We believe in treatment plans that are built on scientific precision and adapted to each person’s skin health journey.The clinic’s design reflects a blend of clinical functionality and wellness-oriented aesthetics, with a focus on comfort, hygiene, and patient privacy. It also provides detailed consultations and diagnostic skin assessments before recommending any procedures.
DermaCute enters the market as Indian consumers increasingly seek holistic and personalised skincare options. With rising awareness around preventive care, regenerative skin therapies, and minimally invasive aesthetic procedures, the clinic aims to meet the expectations of a discerning, health-conscious audience.The launch of DermaCute adds to Mumbai’s growing landscape of specialised skin clinics, reinforcing the shift toward technology-enabled, doctor-led skincare in India’s urban centres.
At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTub